Table 1 Frequency of COX-2 overexpression in colorectal tumors
Tumor type | Total | COX-2 negative | COX-2 weak (1+) overexpression | COX-2 strong (2+) overexpression | COX-2 any (1+, 2+) overexpression |
|---|---|---|---|---|---|
Hyperplastic polyp (HP) | 24 | 21 (88%) | 2 (8.3%) | 1 (4.2%) | 3 (13%) |
Sessile serrated polyp/adenoma (SSA) | 7 | 5 (71%) | 2 (29%) | 0 | 2 (29%) |
Mixed polyp with SSA and adenoma (MP) | 5 | 4 (80%) | 1 (20%) | 0 | 1 (20%) |
Total HP, SSA and MP | 36 | 30 (83%) | 5 (14%) | 1 (2.8%) | 6 (17%) |
Traditional serrated adenoma | 27 | 8 (30%) | 14 (52%) | 5 (19%) | 19 (70%) |
Tubular adenoma (TA) | 393 | 154 (39%) | 132 (34%) | 107 (27%) | 239 (61%) |
Tubulovillous adenoma (TVA) | 109 | 49 (45%) | 27 (25%) | 33 (30%) | 60 (55%) |
Villous adenoma (VA) | 13 | 5 (38%) | 5 (38%) | 3 (23%) | 8 (62%) |
Total non-serrated adenomas (TA, TVA, and VA) | 515 | 208 (40%) | 164 (32%) | 143 (28%) | 307 (60%) |
Adenoma with intramucosal carcinoma | 33 | 8 (24%) | 11 (33%) | 14 (42%) | 25 (76%) |
Adenocarcinoma with serration | 96 | 13 (14%) | 18 (19%) | 65 (68%) | 83 (86%) |
Adenocarcinoma without serration | 111 | 18 (16%) | 23 (21%) | 70 (63%) | 93 (84%) |
Total adenocarcinomas | 207 | 31 (15%) | 41 (20%) | 135 (65%) | 176 (85%) |